Oncogenic tyrosine kinases and the DNA-damage response

Nature Reviews Cancer

Volumn 2, Issue 5, 2002, Pages 351-360

  Skorski, Tomasz ^a  

^a Temple University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSTATIC AGENT; PROTEIN TYROSINE KINASE; DNA; ONCOPROTEIN;

APOPTOSIS; BREAST CARCINOMA; CANCER CELL; COLON CARCINOMA; DISEASE ACTIVITY; DISEASE ASSOCIATION; DNA DAMAGE; DNA REPAIR; ENZYME INDUCTION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC STABILITY; GENOME; HEMATOLOGIC MALIGNANCY; IRRADIATION; LUNG CARCINOMA; MALIGNANT TRANSFORMATION; ONCOGENE; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVIEW; RISK FACTOR; HUMAN; METABOLISM; NEOPLASM; PHYSIOLOGY; ULTRAVIOLET RADIATION;

APOPTOSIS; DNA DAMAGE; DNA, NEOPLASM; HUMANS; NEOPLASMS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; ULTRAVIOLET RAYS;

EID: 0036560577     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc799     Document Type: Review

References (129)

1. Kolibaba, K. S. & Druker, B. J. Protein tyrosine kinases and cancer. Biochim. Biophys. Acta 1333, F217-F248 (1997).
2. Blume-Jensen, P. & Hunter, T. Oncogenic kinase signalling. Nature 411, 355-365 (2001).
3. Tatosyan, A. G. & Mizenina, O. A. Kinases of the Src family: structure and functions Biochemistry 65, 49-58 (2000).
4. Porter, A. C. & Vaillancourt, R. R. Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Oncogene 17, 1343-1352 (1998).
5. Sawyers, C. L. Signal transduction pathways involved in EBCR-ABL transformation. Baillieres Clin. Haematol. 10, 223-231 (1997).
6. Amarante-Mendes, G. P. et al. BCR-ABL exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome c and activation of caspase-3. Blood 91, 1700-1705 (1998). Shows that BCR-ABL can reduce apoptosis that is induced by genotoxic drugs by inhibiting the release of cytochrome c from mitochondria.
7. Masumoto, N., Nakano, S., Fujishima, H., Kohno, K. & Niho, Y. v-SRC induces cisplatin resistance by increasing the repair of cisplatin-DNA interstrand cross-links in human gallbladder adenocarcinoma cells. Intr. J. Cancer 80, 731-737 (1999).
8. Yu, D. & Hung, M. C. Role of ERBB2 in breast cancer chemosensitivity. Bioessays 22, 673-680 (2000).
9. Bedi, A. et al. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood 86, 1148-1158 (1995).
10. Dubrez, L. et al. BCR-ABL delays apoptosis upstream of procaspase-3 activation. Blood 91, 2415-2422 (1998).
11. Maru, Y., Bergmann, E., Coin, F., Egly, J. M. & Shibuya, M. TFIIH functions are altered by the P210BCR-ABL oncoprotein produced on the Philadelphia chromosome. Mutat. Res. 483, 83-88 (2001).
12. Nishii, K. et al. ts BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block. Oncogene 13, 2225-2234 (1996). Shows that DNA-damage-induced G2/M delay has an essential role in BCR-ABL-mediated drug resistance.
13. Slupianek, A. et al. BCR/ABL regulates mammalian RecA homologs, resulting in during resistance. Mol. Cell 8, 795-806 (2001). Provides the first evidence that BCR-ABL stimulates RAD51 and HRR, identifies the signalling pathways that regulate RAD51 and implicates RAD51 in BCR-ABL-dependent drug resistance.
14. cs and exert a negative influence on NHEJ.
15. Abrecht, T. et al. Primary proliferating immature myeloid cells from CML patients are not resistant to induction of apoptosis by DNA damage and growth factor withdrawal Br. J. Haematol. 95, 501-507 (1996).
16. Amos, TA. et al. Apoptosis in chronic myeloid leukaemia: normal responses by progenitor cells to growth factor deprivation, X-irradiation and glucocorticoids. Br. J. Haematol. 91, 387-393 (1995).
17. Pegram, M. D. et al. The effect of HER2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 15, 537-547 (1997).
18. el-Deiry, W. S. Role of oncogenes in resistance and killing by cancer therapeutic agents. Curr. Opin. Oncol. 9, 79-87 (1997).
19. Harrison, O. J. Molecular mechanisms of drug resistance in tumours. J. Pathol. 175, 7-12 (1995).
20. Goldie, J. H. Modelling the process of drug resistance. Lung Cancer 10, S91-S96 (1994).
21. Pietras, R. J. et al. Antibody to HER2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9, 1829-1838 (1994).
22. Dubrez, L., Goldwasser, F., Genne, P., Pommier, Y. & Solary, E. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors. Leukemia 9, 1013-1024 (1995).
23. Cambier, N., Chopra, R., Strasser, A., Metcalf, D. & Elefanty, A. G. BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner. Oncogene 16, 335-348 (1998).
24. Strano, S. et al. From p63 to p53 across p73. FEBS Lett. 490, 163-170 (2001).
25. Aebi, S. et al. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin. Cancer Res. 3, 1763-1767 (1997).
26. Coultas, L. & Strasser, A. The molecular control of DNA damage-induced cell death. Apoptosis 5, 491-507 (2000).
27. Modesti, M. & Kanaar, R. DNA repair: spot(light)s on chromatin. Curr. Biol. 11, R229-R232 (2001).
28. Norbury, C. J. & Hickson, I. D. Cellular responses to DNA damage. Annu. Rev. Pharmacol. Toxicol. 41, 367-401 (2001).
29. Vispe, S., Cazaux, C., Lesca, C. & Defais, M. Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation. Nucleic Acids Res. 26, 2859-2864 (1998).
30. Dasika, G. K. et al. DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis. Oncogene 18, 7883-7899 (1999). Presents the interplay between checkpoints and DNA repair in health and disease.
31. Shi, Y. A structural view of mitochondria-mediated apoptosis. Nature Struct. Biol. 8, 394-401 (2001).
32. 1 work together to protect leukaemia cells from genotoxic treatment.
33. Michel, B. et al. Rescue of arrested replication forks by homologous recombination Proc. Natl Acad. Sci. USA 98, 8181-8188 (2001).
34. Sattler, M. et al. The BCFL/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J. Biol. Chem. 275, 24273-24278 (2000).
35. Majsterek, I. et al. Is BCR/ABL-mediated increase in the effectiveness of DNA repair involved in the cancer cells drug resistance? Cell Biol. Int. (in the press).
36. Hoeijmakers, J. H. Genome maintenance mechanisms for preventing cancer. Nature 411, 366-374 (2001).
37. 1 and discusses their role in genomic stability/instability.
38. Raderschall, E. et al. Elevated levels of RAD51 recombination protein in tumor cells. Cancer Res. 62, 219-225 (2002).
39. Collis, S. J. et al. Ribozyme minigene-mediated RAD51 down-regulation increases radiosensitivity of human prostate cancer cells. Nucleic Acids Res. 29, 1534-1538 (2001).
40. Pierce, A. J., Hu, P., Han, M., Ellis, N. & Jasin, M. Ku DNA end-binding protein modulates homologous repair of double-strand breaks in mammalian cells. Genes Dev. 15, 3237-3242 (2001).
41. Tsai, C. M., Chang, K. T., Li, L., Perng, R. P. & Yang, L. Y. Interrelationships between cellular nucleotide excision repair, cisplatin cytotoxicity, HER2/neu gene expression, and epidermal growth factor receptor level in non-small cell lung cancer cells. Jpn. J. Cancer Res. 91, 213-222 (2000).
42. Zhou, B. B. & Elledge, S. J. The DNA damage response: putting checkpoints in perspective. Nature 408, 433-439 (2000).
43. Shapiro, G. I. & Harper, J. W. Anticancer drug targets: cell cycle and checkpoint control. J. Clin. Invest. 104, 1645-1653 (1999).
44. Bracey, T. S., Williams, A. C. & Paraskeva, C. Inhibition of radiation-induced G2 delay potentiates cell death by apoptosis and/or the induction of giant cells in colorectal tumor cells with disrupted p53 function. Clin. Cancer Res. 3, 1371-1381 (1997).
45. Chan, T. A., Hermeking, H., Lengauer, C., Kinzler, K. W. & Vogelstein, B 14-3-3σ is required to prevent mitotic catastrophe after DNA damage. Nature 401, 616-620 (1999).
46. Elledge, S. J. Cell cycle checkpoints: preventing an identity crisis. Science 274, 1664-1672 (1996).
47. Chen, G. & Hitomi, M. Dissociation of CDK2 from cyclin A in response to the topoisomerase II inhibitor etoposide in v-SRC-transformed but not normal NIH 3T3 cells. Exp. Cell Res. 249, 327-336 (1999).
48. Stiewe, T., Parssanedjad, K., Esche, H., Opalka, B. & Putzer, B. M. E1A overcomes the apoptosis block in BCR-ABL+ leukemia cells and renders cells susceptible to induction of apoptosis by chemotherapeutic agents. Cancer Res. 60, 3957-3964 (2000).
49. Salloukh, H. F., Vowles, I., Heisterkamp, N., Groffen, J. & Laneuville, P. Early events in leukemogenesis in p190BCR-ABL transgenic mice. Oncogene 19, 4362-4374 (2000).
50. Quackenbush, R. C. et al. Analysis of the biologic properties of p230 BCR-ABL reveals unique and overlapping properties with the oncogenic p185 and p210 BCR-ABL tyrosine kinases. Blood 95, 2913-2921 (2000).
51. Voncken, J. W. et al. BCR/ABL p210 and p190 cause distinct leukemia in transgenic mice. Blood 86, 4603-4611 (1995).
52. Ilaria, R. L. Jr & Van Etten, R. A. p210 and p190(BCR-ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J. Biol. Chem. 271, 31704-31710 (1996).
53. Li, G. M. The role of mismatch repair in DNA damage-induced apoptosis. Oncol. Res. 11, 393-400 (1999).
54. Makin, G. & Hickman, J. A. Apoptosis and cancer chemotherapy. Cell Tissue Res. 301, 143-152 (2000).
55. L. Oncogene 16, 1383-1390 (1998).
56. L expression and reverses the transformed phenotype of cells overexpressing EGF and HER2 receptors. Oncogene 18, 4654-4662 (1999).
57. L, and tamoxifen-induced apoptosis in human MCF-7 breast cancer cells. Clin. Cancer Res. 2, 1215-1219 (1996).
58. L. J. Exp. Med. 191, 977-984 (2000).
59. Skorski, T. et al. Transformation of hematopoietic cells by BCR-ABL requires activation of a PI3K/AKT-dependent pathway. EMBO J. 16, 6151-6161 (1997).
60. Wang, Z. H. et al. Expression of BCL2 and BAX in EGFR-antisense transfected and untransfected glioblastoma cells. Anticancer Res. 19, 4167-4170 (1999).
61. Li, Y., Bhuiyan, M. & Sarkar, F. H. Induction of apoptosis and inhibition of c-ERBB2 in MDA-MB-435 cells by genistein. Int. J. Oncol. 15, 525-533 (1999).
62. Carson, W. E., Haldar, S., Baiocchi, R. A., Croce, C. M. & Caligiuri, M. A. The c-KIT ligand suppresses apoptosis of human natural killer cells through the upregulation of BCL2. Proc. Natl Acad. Sci. USA 91, 7553-7557 (1994).
63. Salomoni, P., Condorelli, F., Sweeney, S. M. & Calabretta, B. Versatility of BCR-ABL-expressing leukemic cells in circumventing proapoptotic BAD effects. Blood 96, 676-684 (2000).
64. Neshat, M. S., Raitano, A. B., Wang, H. G., Reed, J. C. & Sawyers, C. L. The survival function of the BCR-ABL oncogene is mediated by BAD-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and RAF. Mol. Cell. Biol. 20, 1179-1186 (2000).
65. L expression in BCR-ABL-transformed cells. Mol. Cell Biol. Res. Commun. 3, 299-305 (2000).
66. Gesbert, F. & Griffin, J. D. BCR-ABL activates transcription of the BCL-X gene through STAT5. Blood 96, 2260-2276 (2000).
67. Datta, S. R. et al. AKT phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 191, 231-241 (1997).
68. del Peso, L., Gonzalez-Garcia, M., Page, C., Herrera, R. & Nunez, G. Interleukin-3-induced phosphorylation of BAD through the protein kinase AKT. Science 278, 687-689 (1997).
69. L. Cell 87, 619-628 (1996).
70. Zhou, B. P. et al. HER2/neu induces p53 ubiquitination via AKT-mediated MDM2 phosphorylation. Nature Cell Biol. 3, 973-982 (2001).
71. Miyashita, T. et al. Tumor suppressor p53 is a regulator of BCL2 and BAX gene expression in vitro and in vivo. Oncogene 9, 1799-1805 (1994).
72. Blume-Jensen, P. Janknecht, R. & Hunter, T. The kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136. Curr. Biol. 8, 779-782 (1998).
73. Aitken, R. J. & Krausz, C. Oxidative stress, DNA damage and the Y chromosome. Reproduction 122, 497-506 (2001).
74. Benhar, M., Dalyot, I., Engelberg, D. & Levtizki, A. Enhanced ROS production in oncogenically transformed cells potentiates c-Jun N-terminal kinase and p38 mitogen-activated protein kinase activation and sensitization to genotoxic stress. Mol. Cell. Biol. 21, 6913-6926 (2001).
75. Laval, J. Role of DNA repair enzymes in the cellular resistance to oxidative stress. Pathol. Biol. 44, 14-24 (1996).
76. Wang, D., Kreutzer, D. A. & Essigmann, J. M. Mutagenicity and repair of oxidative DNA damage: insights from studies using defined lesions. Mutat. Res. 400, 99-115 (1998).
77. Kelman, Z. et al. Rearrangements in the p53 gene in Philadelphia chromosome positive chronic myelogenous leukemia. Blood 74, 2318-2324 (1989).
78. Eyfjord, J. E. et al. TP53 abnormalities and genetic instability in breast cancer. Acta Oncol. 34, 663-667 (1995).
79. Skorski, T. et al. Blastic transformation of p53-deficient bone marrow cells by p210BCR-ABL tyrosine kinase. Proc. Natl Acad. Sci. USA 93, 13137-13142 (1996).
80. Honda, H. et al. Acquired loss of p53 induces blastic transformation in p210BCR-ABL-expressing hematopoietic cells: a transgenic study for blast crisis of human CML. Blood 95, 1144-1150 (2000).
81. Salloukh, H. F. & Laneuville, P. Increase in mutant frequencies in mice expressing the BCR-ABL activated tyrosine kinase. Leukemia 14, 1401-1404 (2000).
82. Kolodner, R. D. & Marsischky, G. T. Eukaryotic DNA mismatch repair. Curr. Opin. Genet. Dev. 9, 89-96 (1999).
83. Flores-Rozas, H. & Kolodner, R. D. Links between replication, recombination and genome instability in eukaryotes. Trends Biochem. Sci. 25, 196-200 (2000).
84. Pierce, A. J. et al. Double-strand breaks and tumorigenesis. Trends Cell. Biol. 11, S52-S59 (2001). Discusses the role of DSB repair in the induction of genomic instability and malignant transformation.
85. Richardson, C. & Jasin, M. Coupled homologous and nonhomologous repair of a double-strand break preserves genomic integrity in mammalian cells. Mol. Cell. Biol. 20, 9068-9075 (2000).
86. Rinehart, F. P., Ritch, T. G., Deininger, P. L. & Schmid, C. W. Renaturation rate studies of a single family of interspersed repeated sequences in human deoxyribonucleic acid. Biochemistry 20, 3003-3010 (1981).
87. Kim, C., Rubin, C. M. & Schmid, C. W. Genome-wide chromatin remodeling modulates the Alu heat shock response. Gene 276, 127-133 (2001).
88. Gebow, D., Miselis, N. & Liber, H. L. Homologous and nonhomologous recombination resulting in deletion: effects of p53 status, microhomology, and repetitive DNA length and orientation. Mol. Cell. Biol. 20, 4028-4035 (2000).
89. Bishop, A. J. & Schiestl, R. H. Homologous recombination as a mechanism of carcinogenesis Biochim. Biophys. Acta 1471, M109-M121 (2001).
90. Kolomietz, E. et al. Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis. Blood 97, 3581-3588 (2001).
91. Jasin, M. Chromosome breaks and genomic instability. Cancer Invest. 18, 78-86 (2000).
92. Cavenee, W. K. et al. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 305, 779-784 (1983).
93. Ikawa, S., Nakagawara, A. & Ikawa, Y. p53 family genes: structural comparison, expression and mutation. Cell Death Differ. 6, 1154-1161 (1999).
94. Hadsell, D. L. et al. Cooperative interaction between mutant p53 and des(1-3)IGF-I accelerates mammary tumorigenesis. Oncogene 19, 889-898 (2000).
95. Li, B., Rosen, J. M., McMenamin-Balano, J., Muller W. J. & Perkins, A. S. neu/ERBB2 cooperates with p53-172H during mammary tumorigenesis in transgenic mice. Mol. Cell. Biol. 17, 3155-3163 (1997).
96. Bartek, J. & Lukas, J. Pathways governing G1/S transition and their response to DNA damage. FEBS Lett. 490, 117-122 (2001).
97. Willers, H. et al. Dissociation of p53-mediated suppression of homologous recombination from G1/S cell cycle checkpoint control. Oncogene 19, 632-639 (2000).
98. Sturzbecher, H. W., Donzelmann, B., Henning, W., Knippschild, U. & Buchhop, S. p53 is linked directly to homologous recombination processes via RAD51/RecA protein interaction. EMBO J. 15, 1992-2002 (1996).
99. Meyn, M. S. High spontaneous intrachromosomal recombination rates in ataxia-telangiectasia. Science 260, 1327-1330 (1993).
100. Rohlfs, E. M. et al. In-frame deletions of BRCA1 may define critical functional domains Hum. Genet. 107, 385-390 (2000).
101. Moynahan, M. E., Chiu, J. W., Koller, B. H. & Jasin, M. Brca1 controls homology-directed. DNA repair. Mol Cell 4, 511-518 (1999).
102. Papavasiliou, F. N. & Schatz, D. G. Cell-cycle-regulated DNA double-stranded break in somatic hypermutation of immunoglobulin genes. Nature 408, 216-221 (2000).
103. Canitrot, Y. et al. Mutator phenotype of BCR-ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase-β. Oncogene 18, 2676-2680 (1999).
104. Jakupciak, J. P. & Wells, R. D. Gene conversion (recombination) mediates expansions of CTG•CAG repeats. J. Biol. Chem. 275, 40003-40013 (2000).
105. Baumann, P. & West, S. C. Role of the human RAD51 protein in homologous recombination and double-stranded-break repair. Trends Biochem. Sci. 23, 247-251 (1998).
106. Bucka, A. & Stasiak, A. RecA-mediated strand exchange traverses substitutional heterologies more easily than deletions or insertions. Nucleic Acids Res. 29, 2464-2470 (2001).
107. Elliott, B. & Jasin, M. Repair of double-strand breaks by homologous recombination in mismatch repair-defective mammalian cells. Mol. Cell. Biol. 21, 2671-2682 (2001).
108. Arnaudeau, C. et al. RAD51 supports spontaneous non-homologous recombination in mammalian cells, but not the corresponding process induced by topoisomerase inhibitors. Nucleic Acids Res. 29, 662-667 (2001).
109. Kohno, K. et al. Construction and characterization of a Rad51 Red52 double mutant as a host for YAC libraries. Gene 188, 175-181 (1997).
110. Thiesing, J. T., Ohno-Jones, S., Kolibaba, K. S. & Druker, B. J. Efficacy of STI-571, an ABL tyrosine kinase inhibitor, in conjunction with other antileukemic agents against BCR-ABL-positive cells. Blood 96, 3195-3199 (2000). Shows the advantage of targeting of BCR-ABL kinase combined with cytotoxic treatment.
111. Skorski, T. et al. Highly efficient elimination of Philadelphia leukemic cells by exposure to BCR-ABL antisense oligodeoxynucleotides combined with mafosfamide. J. Clin. Invest. 92, 194-202 (1993).
112. Fang, G. et al. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes BCR-ABL-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood 96, 2246-2253 (2000).
113. Donato, N. J., Wu, J. Y., Zhang, L., Kantarjian, H. & Talpaz, M. Down-regulation of interleukin-3/granulocyte-macrophage colony-stimulating factor receptor β-chain in BCR-ABL(+) human leukemic cells: association with loss of cytokine-mediated STAT5 activation and protection from apoptosis after BCR-ABL inhibition. Blood 97, 2846-2853 (2001).
114. Druker, B. J. et al. Chronic myelogenous leukemia. Hematology 87-112 (2001).
115. Carter, P. Improving the efficacy of antibody-based cancer therapies. Nature Rev. Cancer 1, 118-129 (2001).
116. Sirotnak, F. M., Zakowski, M. F., Miller, V. A. Scher, H. I. & Kris, M. G. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD 1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. 6, 4885-4892 (2000).
117. Roger, R. et al. BCR-ABL does not prevent apoptotic death induced by human natural killer or lymphokine-activated killer cells. Blood 87, 1113-1122 (1996).
118. Fuchs, E. J., Bedl, A., Jones, R. J. & Hess, A. D. Cytotoxic T cells overcome BCR-ABL-mediated resistance to apoptosis. Cancer Res. 55, 463-466 (1995).
119. Falkenburg, J. H. et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood 94, 1201-1208 (1999).
120. + hematopoietic progenitor cells. J. Immunol. 165, 4133-4140 (2000).
121. Nieborowska-Skorska, M. et al. Oncogene-targeted antisense oligodeoxynucleotides combined with chemotherapy or immunotherapy: a new approach for tumor treatment? Folia Histochem. Cytobiol. 32, 35-40 (1994).
122. Mailand, N. et al. Rapid destruction of human CDC25A in response to DNA damage. Science 288, 1425-1429 (2000).
123. Falck, J., Malland, N., Syljuasen, R. G., Bartek, J. & Lukas, J. The ATM-CHK2-CCD25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 410, 842-847 (2001).
124. Taylor, W. R. & Stark, G. R. Regulation of the G2/M transition by p53. Oncogene 20, 1803-1815 (2001).
125. Chan, T. A., Hwang, R. M., Hermeking, H., Kinzler, K. W. & Vogelstein, B. Cooperative effects of genes controlling the G(2)/M checkpoint. Genes Dev. 14, 1584-1588 (2000).
126. Shah, J. V. & Cleveland, D. W. Waiting for anaphase: MAD2 and the spindle assembly checkpoint. Cell 103, 997-1000 (2000).
127. Antonsson, B. & Martinou, J. C. The BCL2 protein family. Exp. Cell Res. 256, 50-57 (2000).
128. Gross, A., McDonnell, J. M. & Korsmeyer, S. J. BCL2 family members and the mitochondria in apoptosis. Genes Dev. 13, 1899-1911 (1999). Presents an overview of the role of BCL2 proteins in the release of cytochrome c from the mitochondria to the cytoplasm.
129. Masson, J. Y. et al. Identification and purification of two distinct complexes containing the five RAD51 paralogs. Genes Dev. 15, 3296-3307 (2001).